ropinirole has been researched along with buspirone in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Carta, M; Cenci, MA; Fisone, G; Håkansson, K; Lundblad, M; Usiello, A | 1 |
| Björklund, A; Carta, M; Garcia, J; Shin, E; Winkler, C | 1 |
| Björklund, A; Carta, M; Fidalgo, C; Lisci, C; Shin, E; Stancampiano, R; Tronci, E | 1 |
1 review(s) available for ropinirole and buspirone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for ropinirole and buspirone
| Article | Year |
|---|---|
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Buspirone; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Indoles; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Purines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Reproducibility of Results; Riluzole; Treatment Outcome | 2005 |
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 5,6-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Buspirone; Cell Count; Creatinine; Disease Models, Animal; Dopamine Agonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Motor Activity; Oxidopamine; Parkinson Disease; Pyridines; Rats; Rats, Sprague-Dawley; Serotonergic Neurons; Serotonin Receptor Agonists; Time Factors | 2012 |
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
Topics: Amphetamine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzazepines; Buspirone; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Mesencephalon; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides; Serotonin Receptor Agonists | 2014 |